- Titel
- Fampridine response in MS patients with gait impairment in a real-world setting
- Untertitel
- Need for new response criteria?
- Zitierfähige Url:
- https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-355261
- Quellenangabe
- Multiple Sclerosis Journal Erscheinungsort: London
Verlag: Sage
Erscheinungsjahr: 2018
Jahrgang: 24
Heft: 10
Seiten: 1337-1346
E-ISSN: 1477-0970 - Erstveröffentlichung
- 2018
- Abstract (EN)
- Objective: The primary objective of this real-world study was to describe the response to fampridine and changes of gait parameters in multiple sclerosis (MS) patients’ walking disability (Expanded Disability Status Scale (EDSS): 4–7) after treatment with fampridine for 2 weeks as recommended by the European Medicines Agency (EMA) and compare it with the overall physician’s judgement. Methods: A total of 211 adult MS patients were analyzed using a multimodal gait assessment including the timed 25-foot walk test (T25FW), 2-minute walking test (2-MWT), 12-item Multiple Sclerosis Walking Scale (MSWS-12), the GAITRite electronic walkway system, and the patients’ clinical global impression (CGI). Multimodal gait assessment was compared with the clinician’s impression of overall improvement after 2 weeks. Results: In total, 189 subjects were included, of which 133 (70.37%) were responders to fampridine (RF), according to physician’s judgement. Looking at independent multimodal gait assessment, RFs showed improvement of 12.60% in the T25FW, 19.25% in the 2-MWT, 21.12% in the MSWS-12, and 6.54% in their Functional Ambulation Profile (FAP) score. The combination of the T25FW and the MSWS-12 would offer the best sensitivity and specificity for determining response to fampridine according to both neurologists’ and patients’ classification. Conclusion: This study provides new information on the use of fampridine in a real-world setting with a large patient sample on the potential benefit of using more definitive responder criteria to fampridine for the clinical setting.
- Andere Ausgabe
- Link zum Artikel, der zuerst in der Zeitschrift 'Multiple sclerosis journal' erschienen ist.
DOI: 10.1177/1352458517720043 - Freie Schlagwörter (DE)
- Multiple Sklerose, Fampridin, 4-Aminopyridin, Gehfähigkeit, Gehdynamik, Gehverhalten, Behandlungserfolg
- Freie Schlagwörter (EN)
- Multiple sclerosis, fampridine, 4-aminopyridine, walking capacity, walking dynamics, treatment response
- Klassifikation (DDC)
- 610
- Verlag
- Sage, London
- Version / Begutachtungsstatus
- publizierte Version / Verlagsversion
- URN Qucosa
- urn:nbn:de:bsz:14-qucosa2-355261
- Veröffentlichungsdatum Qucosa
- 04.11.2019
- Dokumenttyp
- Artikel
- Sprache des Dokumentes
- Englisch
- Lizenz / Rechtehinweis
